Third generation beta-blockers: current state of research on vasodilating beta-blockers

被引:0
作者
Ladage, Dennis [1 ]
Reidenbach, Christian [1 ]
Lichtenthal, Albert [2 ]
Schwinger, Robert [1 ]
Brixius, Klara [1 ]
机构
[1] Deutsch Sporthochschule Koln, Inst Herz Kreislaufforschung, Abt Mol & Zellulare Sportmed, Am Sportpk Mungersdorf 6, D-50933 Cologne, Germany
[2] Deutsche Fachgesellschaft Neuromentale Med, Essen, Germany
关键词
Beta-blocker; nebivolol; hypertension; eNOS; metabolic syndrome;
D O I
10.1007/s10354-009-0650-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Nebivolol (Nomexor (R)) is a third generation, vasodi-lating beta-blocker with a high beta(1)-adrenoceptor selectivity. Nebivolol acts as an agonist at the beta(3) adrenoceptor as well as the estrogen receptor thereby releasing nitric oxide in blood vessels via eNOS. Pleiotropic effects of nebivolol furthermore include a positive influence on cholesterol and triglycerides and a decrease in thrombocyte activity. Nebivolol is recommended in the guidelines of the European cardiac society (ESC) for patients with metabolic syndrome. Nebivolol's main properties in combination with its broad range of beneficial pleiotropic effects allow it to be clearly distinguished from other second and third generation beta-blockers.
引用
收藏
页码:211 / 218
页数:8
相关论文
共 26 条
[1]  
Rosei EA, 2007, DRUGS, V67, P1097
[2]   Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells [J].
Brehm, BR ;
Wolf, SC ;
Bertsch, D ;
Klaussner, M ;
Wesselborg, S ;
Schüler, S ;
Schulze-Osthoff, K .
CARDIOVASCULAR RESEARCH, 2001, 49 (02) :430-439
[3]   β-blockers of the third generation inhibit endothelin-1 liberation, mRNA production and proliferation of human coronary smooth muscle and endothelial cells [J].
Brehm, BR ;
Bertsch, D ;
von Fallois, J ;
Wolf, SC .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2000, 36 :S401-S403
[4]   Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients [J].
Celik, T ;
Iyisoy, A ;
Kursaklioglu, H ;
Kardesoglu, E ;
Kilic, S ;
Turhan, H ;
Yilmaz, MI ;
Ozcan, O ;
Yaman, H ;
Isik, E ;
Fici, F .
JOURNAL OF HYPERTENSION, 2006, 24 (03) :591-596
[5]   Nebivolol and its 4-keto derivative increase nitric oxide in endothelial cells by reducing its oxidative inactivation [J].
Cominacini, L ;
Pasini, AF ;
Garbin, U ;
Nava, C ;
Davoli, A ;
Criscuoli, M ;
Crea, A ;
Sawamura, T ;
Lo Cascio, V .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 42 (10) :1838-1844
[6]   Endothelial β3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation β-blocker nebivolol [J].
Dessy, C ;
Saliez, J ;
Ghisdal, P ;
Daneau, G ;
Lobysheva, II ;
Frérart, F ;
Belge, C ;
Jnaoui, K ;
Noirhomme, P ;
Feron, O ;
Balligand, JL .
CIRCULATION, 2005, 112 (08) :1198-1205
[7]   A comparison of atenolol and nebivolol in isolated systolic hypertension [J].
Dhakam, Zahid ;
Yasmin ;
McEniery, Carmel M. ;
Burton, Tim ;
Brown, Morris J. ;
Wilkinson, Ian B. .
JOURNAL OF HYPERTENSION, 2008, 26 (02) :351-356
[8]   Effects of nebivolol on left ventricular function in elderly patients with chronic heart failure: results of the ENECA study [J].
Edes, I ;
Gasior, Z ;
Wita, K .
EUROPEAN JOURNAL OF HEART FAILURE, 2005, 7 (04) :631-639
[9]   Effects of nebivolol on human platelet aggregation [J].
Falciani, M ;
Rinaldi, B ;
D'Agostino, B ;
Mazzeo, F ;
Rossi, S ;
Nobili, B ;
Rossi, F ;
Filippelli, A .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2001, 38 (06) :922-929
[10]   FASTTRACK Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS) [J].
Flather, MD ;
Shibata, MC ;
Coats, AJS ;
Van Veldhuisen, DJ ;
Parkhomenko, A ;
Borbola, J ;
Cohen-Solal, A ;
Dumitrascu, D ;
Ferrari, R ;
Lechat, P ;
Soler-Soler, J ;
Tavazzi, L ;
Spinarova, L ;
Toman, J ;
Böhm, M ;
Anker, SD ;
Thompson, SG ;
Poole-Wilson, PA .
EUROPEAN HEART JOURNAL, 2005, 26 (03) :215-225